Table 2.

Characteristics of PhTNS-based drugs.

Drug	Particle Size, nm	Zeta Potential, mV	Content of Drug, mg	Percentage of Drug in Nanoparticles, %
Phospholipid nanoparticles	28.9 ± 1.2	−3.9 ± 1.1	-	-
Doxorubicin	19.2 ± 3.1	6.5 ± 0.8	13.0	96
Indomethacin	21.9 ± 1.9	−12.9 ± 0.6	23.8	95
Umifenovir	8.4 ± 2.6	43.8 ± 1.8	24.6	98.3
Diclofenac	12.9 ± 3.0	−46.6 ± 1.5	23.0	92
Budesonid	22.4 ± 4.6	−1.6 ± 0.2	5.0	100
Prednisolon	18.3 ± 4.1	−4.6 ± 1.3	14.7	98
Chlorin e6	21.2 ± 3.3	−25.5 ± 4.0	12.3	98.4